CG
RLMD icon

Cutler Group’s Relmada Therapeutics RLMD Stock Holding History

Cutler Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$41K Sell
9,000
-300
-3% -$1.45K 0.01% 756
2023
Q4 		$38K Hold
9,300
– – ﹤0.01% 1608
2023
Q3 		$27K Hold
9,300
– – ﹤0.01% 1833
2023
Q2 		$22K Hold
9,300
– – ﹤0.01% 1808
2023
Q1 		$21K Sell
9,300
-15,100
-62% -$52.1K ﹤0.01% 1904
2022
Q4 		$85K Buy
24,400
+13,918
+133% +$122K 0.01% 1261
2022
Q3 		$388K Buy
10,482
+7,815
+293% +$217K 0.03% 649
2022
Q2 		$50K Sell
2,667
-7,079
-73% -$154K ﹤0.01% 1947
2022
Q1 		$263K Buy
9,746
+9,546
+4,773% +$197K 0.01% 1026
2021
Q4 		$4K Sell
200
-1,400
-88% -$31.1K ﹤0.01% 4382
2021
Q3 		$41K Buy
1,600
+400
+33% +$10.7K ﹤0.01% 2678
2021
Q2 		$38K Buy
1,200
+500
+71% +$17.4K ﹤0.01% 2730
2021
Q1 		$24K Buy
700
+540
+338% +$18.9K ﹤0.01% 3070
2020
Q4 		$5K Sell
160
-40
-20% -$1.37K ﹤0.01% 3692
2020
Q3 		$7K Buy
+200
New +$7.73K ﹤0.01% 3265
2020
Q2 		– Sell
-900
Closed -$38K – 4781
2020
Q1 		$30K Buy
+900
New +$36.3K ﹤0.01% 2057

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cutler Group's RLMD Position: Q1 2024 in Review

Cutler Group reduced its Relmada Therapeutics (RLMD) stake by 3.2% in Q1 2024, selling an estimated $1.45K and leaving 9,000 shares worth $41K. The position accounts for 0.01% of the portfolio, ranked #756.

Cutler Group first reported a position in RLMD in Q1 2020 and has held it in 16 quarters since. The position peaked at $388K in Q3 2022. 93 funds tracked by Wall St. Rank hold RLMD as of Q1 2024.

  • Cutler Group held 9,000 shares of Relmada Therapeutics worth $41K as of Q1 2024.
  • Cutler Group sold 300 Relmada Therapeutics shares in Q1 2024, an estimated $1.45K.
  • Relmada Therapeutics made up 0.01% of Cutler Group's portfolio in Q1 2024, its #756 holding.
  • Cutler Group first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 16 quarters since.
  • Cutler Group's Relmada Therapeutics position peaked at $388K in Q3 2022.
  • 93 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.